Drug intelligence / Profile preview

polyphyllin I

Development stage
Preclinical
Modality
Classical Binding Small Molecules → Small Molecules
Administration
Experimental Only (not Clinically Approved, Laboratory Use; Routes In Animal/xenograft Models: Intraperitoneal, Oral, Possibly Intravenous In Mouse Studies[3][7])
01

Overview

Polyphyllin I is a **steroidal saponin** isolated from the rhizome of *Paris polyphylla* (Chong Lou) and other related species[8][2][1]. It exhibits potent **anticancer** activity by inducing cell death, inhibiting proliferation, and limiting invasion in diverse tumor cell lines including liver, breast, lung, gastric, colon, and osteosarcoma cells[3][4][6][8][9]. Mechanistically, polyphyllin I triggers multiple types of regulated cell death:\n- **Apoptosis:** Promotes programmed cell death in various tumor models[1][4].\n- **Autophagic cell death:** Induces autophagy via increased reactive oxygen species (ROS) and suppression of AKT/mTOR signaling[9].\n- **Ferroptosis:** Promotes iron-dependent oxidative cell death by modulating NRF2/FTH1 pathway and increasing lipid peroxidation[7]. Additional effects include impairment of tumor vasculature by inhibiting vasculogenic mimicry (the PI3K-Akt-Twist1-VE-cadherin pathway)[3], and suppression of STAT3 phosphorylation in gastric cancer cells[4]. Polyphyllin I is primarily used experimentally and in traditional Chinese medicine; clinical development is ongoing, focusing predominantly on oncology indications[3][4][7][8][9].

Other names
Chong Lou saponin I
02

Targets

STAT3 (Signal Transducer and Activator of Transcription 3)FTH1 (Ferritin heavy chain 1)TWIST1CTNNB1 (Beta-catenin)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)VEGFC (VEGF-C)CDH5 (Vascular endothelial cadherin)

Beyond the preview

Go deeper on polyphyllin I.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on polyphyllin I.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call